John DiPersio, MD, PhD

Blood and Marrow Transplant & Cellular/Gene Therapy Specialist, Hematologic Oncologist, Medical Oncologist

John DiPersio

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Clinical Expertise

  • Bone Marrow Transplantation

  • Leukemia

Primary Academic Title

Virginia E. and Sam J. Golman Endowed Professorship of Medicine, Pathology & Immunology; Professor of Pediatrics; Director, Center for Gene and Cellular Immunotherapy, WashU Medicine

Board Certification

  • 1984: American Board of Internal Medicine, Internal Medicine
  • 1987: American Board of Internal Medicine, Medical Oncology
  • 1988: American Board of Internal Medicine, Hematology

Training

  • 1980 - 1984: Intern and Resident, Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
  • 1984 - 1987: Fellow, Hematology/Oncology, University of California, Los Angeles, CA

Education

  • 1980: MD/PhD, Microbiology, University of Rochester, Rochester, NY

Research & Select Publications

Research Interest

Molecular biology of cytokine receptor signaling; use and manipulation of mobilized peripheral blood stem cells for autologous and allogeneic transplantation; genetic manipulation of T cells using suicide genes; and targeted gene expression in early hematopoietic stem cells.

Research Publications

NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas
Authors:

Butt OH, Singhal K, Luo J, one or more additional authors omitted DiPersio JF, one or more additional authors omitted Campian JL

Journal & Year:

Clin Cancer Res | 2026

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT
Authors:

Mushtaq MU, DiPersio JF, Azzi J, one or more additional authors omitted Muffly LS

Journal & Year:

Blood | 2026

BACH2 regulates T cell lineage state to enhance CAR T cell function
Authors:

Chang TC, Heard A, Lattin J, one or more additional authors omitted DiPersio JF, one or more additional authors omitted Singh N

Journal & Year:

Nat Immunol | 2026

Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma
Authors:

Li YD, Giles DA, Huang Y, one or more additional authors omitted DiPersio JF, one or more additional authors omitted Chheda MG

Journal & Year:

Nat Commun | 2026

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
Authors:

Pilcher WC, Yao L, Gonzalez-Kozlova E, one or more additional authors omitted DiPersio JF, one or more additional authors omitted Bhasin M

Journal & Year:

Nat Cancer | 2026

The cancer genome and the birth of precision medicine
Authors:

DiPersio JF

Journal & Year:

Haematologica | 2025

Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor …
Authors:

Koehne G, Mushtaq MU, Muffly LS, one or more additional authors omitted DiPersio JF

Journal & Year:

JCO Precis Oncol | 2025

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
Authors:

Ghobadi A, Aldoss I, Maude SL, one or more additional authors omitted DiPersio JF

Journal & Year:

Blood | 2025

Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activity
Authors:

Thomas R, Ritchey JK, DiPersio JF, Kim MY

Journal & Year:

Mol Ther | 2025

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
Authors:

Arellano ML, Thirman MJ, DiPersio JF, one or more additional authors omitted Blachly JS

Journal & Year:

Blood | 2025

Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study
Authors:

Frigault MJ, Maziarz RT, Park JH, one or more additional authors omitted DiPersio JF

Journal & Year:

Blood | 2025

Clonal hematopoiesis landscape in frequent blood donors
Authors:

Karpova D, Huerga Encabo H, Donato E, one or more additional authors omitted DiPersio JF, one or more additional authors omitted Trumpp A

Journal & Year:

Blood | 2025

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation
Authors:

Abboud R, Schroeder MA, Rettig MP, one or more additional authors omitted DiPersio JF

Journal & Year:

Blood | 2025

Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial
Authors:

Ghobadi A, Caimi PF, Reese JS, one or more additional authors omitted DiPersio J, one or more additional authors omitted de Lima M

Journal & Year:

EClinicalMedicine | 2025

Severe acute cutaneous-only graft-versus-host disease after late relapse of chronic myeloid leukemia and ultraviolet B phototherapy
Authors:

Beeler JS, Peravali R, Augustin KM, one or more additional authors omitted DiPersio JF

Journal & Year:

Haematologica | 2025